SBIR-STTR Award

Automated Synthesis Of Large DNA Fragments
Award last edited on: 3/9/06

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$2,576,570
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
John T Mulligan

Company Information

Blue Heron Biotechnology Inc (AKA: Finch Technologies Inc)

22310 20th Avenue SE Suite 100
Bothell, WA 98021
   (425) 368-5000
   N/A
   www.blueheronbio.com
Location: Single
Congr. District: 01
County: Snohomish

Phase I

Contract Number: 1R43GM062093-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2000
Phase I Amount
$127,063
Current methods for the synthetic manufacture of large fragments of DNA, a process commonly referred to as "gene synthesis," are expensive, labor- intensive and slow. We propose to develop a novel automated, solid-phase system for gene synthesis that will reduce costs and speed delivery times. Solid-phase synthesis has already been shown to work on a limited scale for constructing DNA fragments of approximately 300 bp in a non-automated fashion. We plan to apply a team of scientists with expertise in molecular biology, nucleic acid chemistry, software development, polymer chemistry and automation to the problem of developing and optimizing solid-phase gene synthesis. Our goal is a robust automation system that will rapidly and inexpensively produce gene-sized fragments of DNA (up to 10,000 bp in length). In Phase I we will focus on developing prototype procedures for solid-phase gene synthesis that are amenable to automation. We will also develop the computer software needed to design and order the oligonucleotides that will be used to assemble the desired fragment of DNA. In Phase II we will develop the instrumentation and software needed for the automation of gene synthesis. PROPOSED COMMERCIAL APPLICATIONS: The commercial applications for cost-effective synthesis of large DNA fragments are extensive. A major bottleneck in many biological research programs is the time-consuming process of cloning and modifying genes to prepare them for detailed analysis. Rapid access to custom-engineered genes could replace a substantial fraction of the total cloning effort in industrial research groups and academic laboratories.

Thesaurus Terms:
biomedical automation, biomedical equipment development, genetic manipulation, nucleic acid chemical synthesis, technology /technique development computer program /software, molecular cloning, oligonucleotide

Phase II

Contract Number: 2R44GM062093-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2003
(last award dollars: 2004)
Phase II Amount
$2,449,507

The long-term objective of this research is to provide researchers with fast, inexpensive access to any DNA sequence. Gene-based research is at the heart of drug discovery today. The ability to acquire and modify genes is integral to much of the basic research supported by the NIH; research which will be the foundation of future therapeutic research. Fast and cost-effective gene synthesis has the potential to improve the speed and productivity of both applied and basic biomedical research and thus to improve healthcare very broadly. This application's specific objective is to build, test and refine an automated system capable of unattended production of 50,000 base pairs of synthetic DNA fragments in less than 18 hours. This system will first be commercialized by incorporating it into Blue Heron Biotechnology's existing automated gene synthesis process. In the future, it could be the basis for a commercial instrument for gene synthesis. The instrument will be based on the novel and innovative technologies for gene assembly developed in the Phase I portion of this research. It will involve both custom-designed instruments and the incorporation of available automation for plate handling and plate storage, novel attachment chemistry and custom-manufactured solid-phase supports.

Thesaurus Terms:
biomedical automation, biomedical equipment development, genetic manipulation, nucleic acid chemical synthesis, technology /technique development artificial intelligence, computer program /software, computer system design /evaluation, molecular cloning, oligonucleotide biotechnology